Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry
Patients with PSO and PsA treated in a real-world dermatology setting with substantial disease factors following biologic initiation were more likely to switch therapies. Those with PASI > 10 and DLQI > 5 switched more frequently than those with PASI ≤ 10 and DLQI ≤ 5.
Authors
- Adam Šíma (ORCID: https://orcid.org/0000-0001-8426-9987)
- Braulio Gomez (ORCID: https://orcid.org/0009-0000-1756-0491)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Silky Beaty (ORCID: https://orcid.org/0000-0002-1071-802X)
- Robert Low (ORCID: https://orcid.org/0000-0002-1995-7094)
- Andrew Blauvelt (ORCID: https://orcid.org/0000-0002-2633-985X)
- Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
- Marie Gurrola
Institutions
- Mount Sinai Hospital (US)
- Swedish Medical Center (US)
- UCB Pharma (United States) (US)
- Oregon Medical Research Center (US)
- Navitas Systems (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1007/s13555-024-01258-1
- Citations
- 7
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Amgen
- Bristol-Myers Squibb
- National Psoriasis Foundation
- Eli Lilly and Company
- Pfizer
- Sanofi
- Gilead Sciences
- Celgene
- Regeneron Pharmaceuticals
- Ortho Dermatologics
- LEO Pharma
- Genentech
- Chugai Pharmaceutical
- UCB US
- Janssen Pharmaceuticals
- UCB Pharma